MAIA Biotechnology (MAIA) investor relations material

Investment profile

• Ateganosine (THIO) is a telomerase-incorporated guanine analog designed to disrupt telomeres and activate antitumor immunity; second-generation agents are in preclinical IND-enabling work.

• The presentation identifies THIO as the only direct telomere-targeting anticancer agent in clinical development.

Clinical progress

• In THIO-101, the 180 mg dose was selected; reported 3L results include 17.8-month median OS, 88% DCR and 38% ORR.

• THIO-101 Part C completed enrollment in July 2026, with 88% DCR confirmed; efficacy data were presented from the July 31, 2026 data cut.

• Ongoing THIO-104 is a pivotal Phase 3 trial of 300 patients; enrollment began in Dec 2025, with 65 enrolled as of Sep 21, 2026, and an interim efficacy analysis targeted for 2027.

• THIO-104 uses OS as its primary endpoint; Bayesian assurance estimates a 96% probability of interim success and 99% at final analysis, based on THIO-101 data and stated assumptions.

Mechanism and broader pipeline

• In NSCLC preclinical models, THIO followed by a checkpoint inhibitor produced 60% complete responses; treated mice had no tumor take after rechallenge with 5x more cancer cells.

• Preclinical studies reported 100% complete responses in CRC models; HCC studies showed complete regression with THIO, radiation and atezolizumab, while THIO followed by pembrolizumab showed activity in SCLC models.

• Planned Phase 2 programs pair THIO with tislelizumab in CRC, SCLC and HCC, with initial safety/efficacy cohorts of ~40 and planned expansion cohorts of ~80 patients.

• Three second-generation telomere-targeting agents are in preclinical IND-enabling development, with rights fully owned and compounds developed in-house.